DAEWOONG PHARMACEUTICAL CO., LTD

Daewoong Pharmaceutical is a top-tier Korean pharmaceutical company. By FY2025 consolidated revenue it ranked sixth among Korean traditional and bio-pharma companies (KRW 1,570.9 bn) and was among only three large traditional drugmakers with a double-digit operating margin (12.5%). The franchise rests on three internally developed products. Nabota is a botulinum toxin sold in the US as Jeuveau through Evolus and is the only Korean toxin approved by the FDA. Fexuclue (fexuprazan) is a P-CAB acid blocker. Envlo (enavogliflozin) is an SGLT2 inhibitor for diabetes. Behind these sit a large domestic prescription (ETC) business anchored by the heritage liver brand Ursa, a fast-growing hospital digital-health distribution business (thynC), and an R&D engine running at about 15.8% of sales. Strategically the company is pivoting from a domestic ETC distributor to a global, product-led company, with Indonesia as its manufacturing hub for ASEAN and the halal market. The defining overhang is the decade-long Medytox trade-secret litigation over the Nabota strain.

---

What the company does

Daewoong Pharmaceutical researches, manufactures and sells finished pharmaceuticals and biologics. It also distributes in-licensed products and medical devices. In the FY2025 annual report it describes its operating activity almost entirely as pharmaceutical manufacturing and sales. Sell-side summaries of DART segment data put this at about 98% of revenue, with service provision at about 2% (Butler.works, citing Q2 2026 filing data). Management and investors, however, track the business by commercial division:

1. ETC (prescription drugs). The largest division: KRW 894.2 bn in FY2025, +4.9% YoY (Dealsite, FY2025 provisional results, 9 Feb 2026). It combines own products (Fexuclue, Envlo/Envlomet, Ursa Rx, Olostar) with in-licensed multinational brands such as Olmetec. Management stated that own-product share of ETC is "close to 60%" and reached 59.0% in Q3 2025 (Kiwoom, Nov 2025). This rising mix is the main driver of margin expansion.

2. Nabota (botulinum toxin type A). KRW 228.9 bn in FY2025, +19% YoY, with about 84% from exports (Dealsite, Feb 2026; Money Today, Jul 2026). It is sold as Jeuveau in the US and Nuceiva in Europe through Evolus, Inc., and through about 80 partner arrangements with approvals in 69 countries (Medigate, Jul 2026).

3. OTC and consumer health. KRW 162.6 bn in FY2025 per Dealsite. Brands include Ursa (OTC version), Impactamin, EzN6, Easydew and Bearse, plus health functional foods. Distribution was broadened in 2025 into the Daiso variety-store channel.

4. Digital healthcare. A distribution and service business built around thynC, a wearable-based inpatient vital-sign monitoring system developed by Seers Technology. Other products are Mobicare (wearable ECG), Abbott FreeStyle Libre continuous glucose monitors, CART BP (ring-type blood-pressure monitor) and WISKY (AI retinal-disease screening). Revenue was KRW 17.0 bn in Q1 2026 (+52%) and KRW 15.7 bn in Q2 2026 (+27%) (Dealsite; Kormedi, Jul 2026).

5. Global/contract manufacturing and "consolidated & other". This line holds subsidiary revenue, chiefly Hanall Biopharma (FY2024 revenue KRW 138.9 bn), and global contract business. Kiwoom puts "consolidated & other" at KRW 154.1 bn (FY2024) and KRW 183.0 bn (FY2025).

Business and revenue model

Product sales dominate: Most revenue is recognised on shipment of finished goods to wholesalers (Korea), partners (exports) or hospitals.

Licensing and milestones: are periodic. Examples: upfronts and milestones on fexuprazan, Envlo and bersiporocin out-licensing; royalty and milestone streams inherited from the 2026 Turn Biotechnologies asset acquisition.

Supply-and-distribution partnering: for exports. Nabota is supplied as finished product to Evolus, which books US retail revenue. Daewoong records export revenue at transfer price, so its toxin revenue tracks Evolus shipment timing rather than US end-demand directly.

Usage-linked service revenue: in digital healthcare. Roughly half of thynC revenue is linked to usage contracts rather than one-off equipment sales (Kiwoom, Apr 2026). That half recurs but builds slowly.

No subscription model: of material size.

Value-chain position

Daewoong is vertically integrated from discovery (Yongin research centre) through API sourcing and finished-dose manufacturing (Hyangnam, Osong) to a large domestic sales force. In March 2026 it moved its domestic wholesale logistics to a "block-type hub wholesaler" model. Korea was divided into 10 regions, and the number of distributors was cut from about 40 to 5 (MTN, Jul 2026). Overseas, it relies on partners in the US/EU and on its own subsidiaries in Indonesia, China (Beijing), Thailand and the US.

Customers and end-markets

• Korean hospitals and clinics, through wholesalers, for ETC.

• Pharmacies and retail (including Daiso) for OTC.

• Aesthetic physicians and dermatology clinics for Nabota, mostly via partners.

• Hospitals (16 of 47 Korean tertiary hospitals, 200+ institutions) for thynC.

• Licensing partners and pharmaceutical companies for technology-transfer deals.

End-markets span gastroenterology, diabetes and metabolic disease, hepatology, cardiovascular, medical aesthetics, and hospital monitoring and digital health.

Company self-description vs. independent characterisation

The company presents itself as a global healthcare company pursuing "first-in-class/best-in-class" innovation and open collaboration. Its signature slogan is "1품 1조" ("one product, one trillion won"), the goal of building single products to KRW 1 tn in annual sales (CEO Lee Chang-jae, AGM March 2025).

Independently, Daewoong is better characterised as a high-quality Korean ETC franchise funding a toxin export growth story. The toxin and digital businesses are the profit-growth engines. The own-NCE franchise (Fexuclue, Envlo) has proven domestically but has not yet scaled internationally, and the long-dated pipeline (bersiporocin, microneedle GLP-1 patch, anti-ageing mRNA) is option value rather than earnings. Nabota contributed about 21% of H1 2026 separate revenue (Money Today, Jul 2026) and a disproportionate share of profit, which makes Evolus shipment cadence the single largest swing factor in quarterly results.

Stated corporate strategy (paraphrased themes)

1. "1품 1조" (one product, one trillion won). Build single own products — Fexuclue, Envlo, Nabota — into KRW 1 tn-a-year global blockbusters (AGM 2024 and 2025).

2. Global expansion. Take Fexuclue into China, Latin America and the Middle East. Build the Nabota new plant to secure cGMP certification and maximise commercial volume (FY2025 results release, Feb 2026).

3. Realise R&D value. Focus R&D investment on obesity and oncology. Out-license assets (bersiporocin) after data readouts.

4. New growth engines / "total healthcare ecosystem." Link wearable devices and data-based services across prevention, diagnosis, treatment and aftercare.

5. Structural profitability. Grow own-product share (about 60%), streamline distribution, and keep investment efficient.

Initiatives in the last 24 months

Medium-term targets and guidance

The company has issued no formal numerical revenue or margin guidance in the sources reviewed. Aspirational targets:

• Nabota KRW 500 bn annual sales by 2030

• Envlo in 50 countries by 2030

• Market cap of KRW 5 tn within 3 years of 2024 and KRW 20 tn within 10 years (CEO Park)

• KRW 1 tn of global new-drug sales by 2030 (stated in 2023)

Botulinum toxin and aesthetics

Nabota / Jeuveau / Nuceiva (prabotulinumtoxinA)

Description: High-purity botulinum toxin type A, 100-unit vial (also lower-unit formats).

Key regulatory standing: Approved by the US FDA (Feb 2019), EMA and Health Canada. Approved in 69 countries, with about 80 country partnerships (Medigate, Jul 2026). The company says it is the only toxin manufacturing facility in Korea or Asia to have passed FDA, EMA and Health Canada inspections (Metro Seoul, May 2023).

Indications: Glabellar lines (aesthetic) as the core. Therapeutic indications are under development in some markets; the Indonesian regulator recommended a post-stroke spasticity trial at the Selatox plant.

Commercial channels: Jeuveau (US) and Nuceiva (EU5 and UK) through Evolus. Evolus also markets in Canada and Australia. Saudi launch Jan 2025. LatAm, Middle East and Southeast Asia through partners. China approval pending after the Sep 2025 refiling (indication: moderate-to-severe glabellar lines, ages 20–65).

China Phase 3 data: 92.2% responder rate at week 4 vs 86.8% for Botox (Inews24, Dec 2021; Dealsite, Sep 2025).

US position: About 13–14% share of the US aesthetic toxin market, ranked No. 2 (Dealsite, Feb 2025; Sidae, Jan 2026; Evolus Q1 2026 call).

Scale: Launched 2014 in Korea. Cumulative sales passed KRW 1 tn by 30 June 2026. FY2025 sales KRW 228.9 bn.

Target: KRW 500 bn annual sales by 2030 (Nabota business head Yoon Jun-su, Jul 2026).

In development: Next-generation aesthetics — a biodegradable collagen-stimulating skin booster, fillers, a medical-cosmetics platform and a recombinant toxin. Earlier plans also listed liquid, long-acting and microneedle toxin formats.

Gastroenterology

Fexuclue (fexuprazan HCl) 40 mg / 10 mg

Mechanism: Potassium-competitive acid blocker (P-CAB). Positioned on faster onset and a longer half-life than PPIs.

Approvals and launches: Korea (Dec 2021, 34th Korean new drug). Philippines (Nov 2022), Ecuador (Jan 2023), Chile (Mar 2023), Mexico (Oct 2023), China (NMPA, Sep 2025). Launched in Indonesia in Sep 2026, targeting a USD 164.3 m anti-ulcer market (Sedaily, Sep 2026). Early in the product's life the company cited entry into 24 countries within 18 months of launch (Kormedi, 2024).

Indications: Erosive esophagitis is the core indication. Gastritis reimbursement was expanded in 2024. The company holds five indications and is running three more trials (Samsung Securities, May 2026):

• Non-erosive reflux disease (Phase 3)

• Gastric ulcer (Phase 3; Korea–Indonesia multiregional trial)

• Injection formulation (Phase 1)

• Post-endoscopy reflux esophagitis (IND approved, Jul 2026)

• H. pylori eradication data presented at DDW 2026, suggesting higher eradication in antibiotic-resistant patients

Commercial: Chong Kun Dang co-promotion ended 31 Aug 2026. Daewoong began sole selling from Sep 2026, with distribution unified under Daewoong from 1 Dec 2026 (Dailypharm, Sep 2026).

Sales: KRW 102.0 bn (FY2024), KRW 94.5 bn (FY2025).

Ursa (ursodeoxycholic acid; Rx and OTC formats)

• Heritage liver brand, first soft-capsule version launched in 1974. Sales of KRW 96.2 bn in FY2024.

• Listed in the Korean gastric-cancer treatment guideline for gallstone prevention after gastrectomy (Dealsite, Feb 2025).

• Kormedi (Oct 2025) notes that Ursa prescriptions benefit from GLP-1 obesity-drug uptake.

Diabetes and metabolic disease

Envlo (enavogliflozin) and Envlomet (enavogliflozin + metformin)

Description: SGLT2 inhibitor; 36th Korean new drug (2022). The fixed-dose metformin combination Envlomet followed about six months later.

Clinical data: The company reports superior glucose lowering vs dapagliflozin in a comparative study.

International: Licensing to Russia/CIS (about KRW 77.1 bn), LatAm via Moksha8 (about KRW 115 bn) and the Middle East via Arcera Life Sciences (partnership expanded 2026).

Targets: 15 countries by 2025 and 50 by 2030 (Kormedi, 2024).

Pipeline: A metformin add-on Phase 3 was approved in 2026. A veterinary canine-diabetes application was filed in Oct 2025, which the company describes as a world first.

Sales: Above KRW 10 bn for the first time in FY2024.

Cardiovascular and other ETC

Olostar: Improved combination product developed in-house (rosuvastatin/olmesartan class), cited in company histories.

Olmetec (olmesartan): In-licensed antihypertensive. Q1 2026 sales fell to KRW 4.7 bn after a raw-material admixture issue.

Luprorelin depot (leuprolide): Prostate cancer generic depot, licensed for the US market (up to about KRW 122.2 bn, 2023).

Other in-licensed multinational ETC brands: Not enumerated product-by-product in the sources reviewed.

OTC and consumer health

• Impactamin (vitamin B), EzN6 (analgesic), Easydew (dermo-cosmetic/skin repair), Bearse (digestive, 1988), Ursa OTC.

• Health functional foods are being combined with OTC operations.

• Indonesian localisation of Easydew, Impactamin and EzN6 under a June 2026 MOU with the Indonesian Pharmacists Association, which targets OTC No. 1 in Indonesia by 2030.

Digital healthcare (distribution and service)

Regenerative and cell therapy

Stem-cell and immune-cell products are developed through the Yongin Cell Therapy Center. They are manufactured for clinical use at the Songdo advanced biologics site (opened Sep 2026) and in Indonesia (DBI, GMP 2024). No commercial products in this area are disclosed in Korea.